Eagle Pharmaceuticals Sees FY23 Adjusted EPS Of $4.20-$4.53 Vs. Consensus of $4.49
Expects 2023 Adjusted EBITDA of $74.0-$80.0 million
Eagle Pharmaceuticals Q4 Adjusted EPS $1.10 Beats $0.83 Estimate, Sales $60.70M Miss $64.26M Estimate
Eagle Pharmaceuticals (NASDAQ:EGRX) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.83 by 32.53 percent. This is a 29.41 percent increase over earnings of $0.85 per share
Bluegreen Vacations, Eagle Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
With US futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Why Fear Level Among US Investors Is Increasing
The CNN Money Fear and Greed index moved to the "Extreme Fear" zone following a sharp drop in the US stocks.
Stocks on the Wall Street tumbled on Friday amid concerns over the U.S. regional banking industry.
Eagle Pharmaceuticals Sees FY23 Adj. EBITDA $74M-$80M; Sees Adj. Non-GAAP EPS $4.20-$4.53 Vs $4.42 Est
Preliminary 2023 Guidance
Adjusted EBITDA of $74.0-$80.0 million5
Adjusted non-GAAP earnings per share of $4.20-$4.536
Adjusted non-GAAP R&D expense of $41.0-$45.0 million
Eagle Pharmaceuticals Receives FDA Approval For Additional Indication For PEMFEXY In Combination With Pembrolizumab And Platinum Chemotherapy
-- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations --
-- Represents the fifth indication for
Eagle Pharmaceuticals Announces FDA Acceptance Of Investigational New Drug Application For CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent For The Adjunct Treatment Of Severe Community-Acquired Bacterial Pneumonia
-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide --
-- Patient enrollment expected to commence as early as the beginning of
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session.
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell
• NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
